The comprehensive genomic analysis of ACC samples has shown few recurrent mutations in known genes and a substantially low mutational burden, confirming the MYB/MYBL1-NFIB fusions as key events in the pathogenesis of ACC and a hallmark of this pathology, being present in more than 50% of cases6,7. This evidence concerns the gene NFIB and adrenal cortex carcinoma.